SIOX VS CYTO Stock Comparison

Performance

SIOX
10/100

SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.

CYTO
10/100

CYTO returned -98.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Forecast

SIOX
82/100

The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.

CYTO

"Forecast" not found for CYTO

Technicals

SIOX
86/100

Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.

CYTO
14/100

CYTO receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Volatility

SIOX
10/100

SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.

CYTO
25/100

CYTO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

Dividend

SIOX
10/100

SIOX does not have a dividend payout ratio.

CYTO

"Dividend" not found for CYTO

Profit

SIOX
10/100

Could not get data for SIOX.

CYTO
13/100

Out of the last 20 quarters, CYTO has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Earnings

SIOX

"Earnings" not found for SIOX

CYTO
44/100

CYTO has missed earnings 2 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Sio Gene Therapies Inc. Common Stock Summary

Nasdaq / SIOX

Healthcare

Biotechnology

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) Summary

Nasdaq / CYTO

Healthcare

Biotechnology

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Power up your portfolio